CompletedNot Applicable

Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma

Italy478 participantsStarted 2021-11-01

Plain-language summary

Outcomes for minimally invasive and open pancreatoduodenectomy for distal cholangiocarcinoma have not been compared. This is an international multicenter propensity score matched cohort study including patients after MIPD or OPD for dCCA. Primary outcomes included overall survival (OS) and disease-free interval (DFI).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Adult patients * Elective upfront curative MIPD or OPD between January 1, 2010 and December 31, 2021 * Pathological confirmed dCCA Exclusion criteria: * Neoadjuvant chemotherapy * Palliative surgical procedures * Intraoperative detection of unresectable disease (i.e., metastasis or locally advanced disease) * Post-operative pathological diagnosis was other than dCCA (e.g., neuroendocrine tumor, polyposis adenoma) * R2 positive resection margin * Pregnancy * Missing primary endpoints

What they're measuring

Overall survival and disease-free interval

Timeframe: 60 months

Trial details

NCT IDNCT05478889

SponsorFondazione Poliambulanza Istituto Ospedaliero

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03-01

View on ClinicalTrials.gov More Distal Cholangiocarcinoma trials